Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver

Zealand Pharma stock suffered its two worst days on record. Here’s what’s next for the weight loss drugmaker

In this article ROP-CH NVO LLY NVO Follow your favorite stocksCREATE FREE ACCOUNT Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy. But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting …